Skip to main content
. 2020 Nov 26;12:549–557. doi: 10.2147/JEP.S259290

Table 3.

Active Trials in SR-aGVHD

Response Phase Intervention
Itacitinib 70.6% (30% CR) Phase I Itacitinib+Tocilizumab NCT04070781
CD3/CD7-IT 60%(50% CR) Phase II CD3/CD7-IT vs Ruxolitinib NCT00640497
Neihulizumab Skin only: 91% Phase I Neihilizumab NCT03327857
FMT Up to 100% Phase II FMT in GI aGVHD NCT04059757

Abbreviation: FMT, fecal microbiota transplant.